https://orcid.org/0000-0002-2390-6505
Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Xiaohua Wang, Liyan Yuan, Xiaoyu Qiu, Bin Yang & Mao-Qiang Man. (2023) Psoriasis and COVID-19 Infection Negatively Impact Each Other: An Analysis of 3581 Cases. Clinical, Cosmetic and Investigational Dermatology 16, pages 1933-1936.
Read now
Read now
Angelo Ruggiero, Matteo Megna, Gabriella Fabbrocini, Luigi Fornaro & Alessia Villani. (2022) Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge. Expert Opinion on Drug Safety 21:10, pages 1249-1257.
Read now
Read now
Gustavo Gomes Resende, Ricardo da Cruz Lage, Samara Quadros Lobê, Amanda Fonseca Medeiros, Alessandra Dias Costa e Silva, Antônio Tolentino Nogueira Sá, Argenil José de Assis Oliveira, Denise Sousa, Henrique Cerqueira Guimarães, Isabella Coelho Gomes, Renan Pedra Souza, Renato Santana Aguiar, Roberto Tunala, Francisco Forestiero, Julio Silvio Souza Bueno Filho & Mauro Martins Teixeira. (2022) Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients – the BISHOP study. Infectious Diseases 54:8, pages 591-599.
Read now
Read now
Yulin Zou & Zudong Meng. (2021) Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19. Journal of Inflammation Research 14, pages 5611-5618.
Read now
Read now
Articles from other publishers (12)
Matteo Megna, Giuseppe Lauletta, Nello Tommasino, Antonia Salsano, Teresa Battista, Angelo Ruggiero, Fabrizio Martora & Luca Potestio. (2024) Management of Psoriasis Patients with Serious Infectious Diseases. Advances in Therapy 41:6, pages 2099-2111.
Crossref
Crossref
María José Valencia López, Anna Meineke, Brigitte Stephan, Stephan Jeff Rustenbach, Anne Kis, Diamant Thaçi, Ulrich Mrowietz, Kristian Reich, Petra Staubach‐Renz, Ralph von Kiedrowski, Henriette Bogena & Matthias Augustin. (2024) SARS‐CoV‐2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest. JDDG: Journal der Deutschen Dermatologischen Gesellschaft.
Crossref
Crossref
Yu-Xin Zheng, Xi-Bei Chen, Zhao-Yuan Wang, Li-Ran Ye, Min Zheng & Xiao-Yong Man. (2024) Biologics protect psoriasis patients from being exacerbated by COVID-19 infection. Heliyon 10:2, pages e24534.
Crossref
Crossref
Pedro M Machado, Martin Schäfer, Satveer K Mahil, Jean Liew, Laure Gossec, Nick Dand, Alexander Pfeil, Anja Strangfeld, Anne Constanze Regierer, Bruno Fautrel, Carla Gimena Alonso, Carla G S Saad, Christopher E M Griffiths, Claudia Lomater, Corinne Miceli-Richard, Daniel Wendling, Deshire Alpizar Rodriguez, Dieter Wiek, Elsa F Mateus, Emily Sirotich, Enrique R Soriano, Francinne Machado Ribeiro, Felipe Omura, Frederico Rajão Martins, Helena Santos, Jonathan Dau, Jonathan N Barker, Jonathan Hausmann, Kimme L Hyrich, Lianne Gensler, Ligia Silva, Lindsay Jacobsohn, Loreto Carmona, Marcelo M Pinheiro, Marcos David Zelaya, María de los Ángeles Severina, Mark Yates, Maureen Dubreuil, Monique Gore-Massy, Nicoletta Romeo, Nigil Haroon, Paul Sufka, Rebecca Grainger, Rebecca Hasseli, Saskia Lawson-Tovey, Suleman Bhana, Thao Pham, Tor Olofsson, Wilson Bautista-Molano, Zachary S Wallace, Zenas Z N Yiu, Jinoos Yazdany, Philip C Robinson & Catherine H Smith. (2023) Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. Annals of the Rheumatic Diseases 82:5, pages 698-709.
Crossref
Crossref
Nicole Maynard & April W. Armstrong. (2023) The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness. Current Dermatology Reports 12:2, pages 45-55.
Crossref
Crossref
Yu Meng, Furong Zeng, Huiyan Sun, Yayun Li, Xiang Chen & Guangtong Deng. (2022) Clinical characteristics and outcomes of patients with COVID‐19 and psoriasis. Journal of Medical Virology 94:12, pages 5850-5857.
Crossref
Crossref
Katerina Bakirtzi, Ilias Papadimitriou, Efstratios Vakirlis, Themis Chatzi-Sotiriou, Dimitrios Ioannides & Eleni Sotiriou. (2022) Long-term efficacy of biologic treatment for psoriasis after COVID-19 infection. Clinical and Experimental Dermatology 47:11, pages 2025-2026.
Crossref
Crossref
Meitong Liu, Huijuan Wang, Lu Liu, Saijin Cui, Xiangran Huo, Zhuoyun Xiao, Yaning Zhao, Bin Wang, Guoqiang Zhang & Na Wang. (2022) Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis. Frontiers in Immunology 13.
Crossref
Crossref
James T. Rosenbaum, Michael H. Weisman, Hedley Hamilton, Cassie Shafer, Elin Aslanyan, Richard A. Howard, Kimberly Ogle, John D. Reveille, Kevin L. Winthrop & Dongseok Choi. (2022) The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment. The Journal of Rheumatology 49:2, pages 225-229.
Crossref
Crossref
María Aparicio, Carlos A. Guillén-Astete, Clementina López-Medina, Carlos Sastre & Fernando J. Rodríguez Martínez. (2021) Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years. Rheumatology and Therapy 9:1, pages 73-94.
Crossref
Crossref
Edward Hadeler, Julie Hong, Megan Mosca, Marwa Hakimi & Tina Bhutani. 2022. Biologic Therapy for Psoriasis. Biologic Therapy for Psoriasis
125
130
.
Andrea Conti, Giovanni Damiani, Roberta Ruggeri, Giulia Odorici, Francesca Farnetani, Paolo Daniele Maria Pigatto & Giovanni Pellacani. (2021)
Switching infliximab in psoriatic patients during
COVID
‐19 pandemics: A real‐life retrospective study comparing intra‐versus interclass switching strategies
. Dermatologic Therapy 34:5.
Crossref
Crossref